Advertisement
Singapore markets closed

  • Straits Times Index

    3,290.70
    +24.75 (+0.76%)
     

  • Nikkei

    38,229.11
    +155.13 (+0.41%)
     

  • Hang Seng

    18,963.68
    +425.87 (+2.30%)
     

  • FTSE 100

    8,433.76
    +52.41 (+0.63%)
     

  • Bitcoin USD

    60,845.85
    -2,473.36 (-3.91%)
     

  • CMC Crypto 200

    1,257.51
    -100.50 (-7.40%)
     

  • S&P 500

    5,222.68
    +8.60 (+0.16%)
     

  • Dow

    39,512.84
    +125.08 (+0.32%)
     

  • Nasdaq

    16,340.87
    -5.40 (-0.03%)
     

  • Gold

    2,366.90
    +26.60 (+1.14%)
     

  • Crude Oil

    78.20
    -1.06 (-1.34%)
     

  • 10-Yr Bond

    4.5040
    +0.0550 (+1.24%)
     

  • FTSE Bursa Malaysia

    1,600.67
    -0.55 (-0.03%)
     

  • Jakarta Composite Index

    7,088.79
    -34.81 (-0.49%)
     

  • PSE Index

    6,511.93
    -30.53 (-0.47%)
     

Novo Nordisk could close biopharma acquisition this year - CEO

Reuters
Danish healthcare company Novo Nordisk CEO Lars Fruergaard Jorgensen speaks during at the company's headquarters in Bagsvaerd near Copenhagen, Denmark February 2, 2017. Scanpix Denmark/Liselotte Sabroe/via REUTERS/File Photo (Reuters)

COPENHAGEN (Reuters) - Novo Nordisk might be able to complete an acquisition within its struggling biopharma business this year, its chief executive told Reuters on Monday.

"It is not always easy to predict when a transaction goes through, but we are in enough ongoing discussions that it might be possible this year if all goes well," CEO Lars Fruergaard Jorgensen said, declining to provide more detail on the potential deal.

Novo announced on Monday it had hired an AstraZeneca executive to head its biopharma business.

(Reporting by Stine Jacobsen; editing by Jason Neely)